On this page
TRIAMCINOLONE ACETONIDE
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 213559-001 | TRIAMCINOLONE ACETONIDE | LOTION | TRIAMCINOLONE ACETONIDE | Prescription | AT | ||
| 213559-002 | TRIAMCINOLONE ACETONIDE | LOTION | TRIAMCINOLONE ACETONIDE | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | July 1, 2020 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250722). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Triamcinolone acetonide lotion, 0.1% is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Apply the 0.1% triamcinolone acetonide lotion to the affected area two to three times daily. Rub in gently. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Gently rub a small amount of lotion into the lesion until it disappears. Reapply the preparation leaving a thin coating on the lesion, cover with pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply triamcinolone acetonide lotion under an occlusive dressing in the evening and to remove the dressing in the morning (i.e.,12-hour occlusion). When utilizing the 12‐hour occlusion regimen, additional lotion should be applied, without occlusion, during the day. Reapplication is essential at each dressing change. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Description
openFDA Drug LabelingDESCRIPTION Triamcinolone Acetonide Lotion, USP is supplied in the following strengths: 0.025%, 0.1%. Each mL of Triamcinolone Acetonide Lotion, USP, 0.025%, 0.1% contains 0.25 mg, 1 mg triamcinolone acetonide, USP in a lotion base containing citric acid, cetyl alcohol, dimethicone, polysorbate 20, propylene glycol, purified water, sorbitan monopalmitate, and stearyl alcohol. It may contain 10% citric acid solution or 10% sodium citrate solution for pH adjustment. Triamcinolone Acetonide is a topical corticosteroid known chemically as 9-Fluoro-11β, 16α, 17, 21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone. The molecular formula is C 24 H 31 FO 6 . It has the following structure: image description
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS , General ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Triamcinolone acetonide lotion, USP 0.1%: plastic squeeze bottles containing 60 mL of lotion (NDC 42571-385-19) Storage Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid freezing. Shake well before using. Distributed by: Micro Labs USA, Inc. Somerset, NJ 08873 Manufactured by: Saptalis Pharmaceuticals, LLC Hauppauge, NY 11788 MADE IN USA 01/22-R2
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: TRIAMCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 72162-2069-6 | 72162-2069 | Bryant Ranch Prepack | 60 mL in 1 BOTTLE, WITH APPLICATOR (72162-2069-6) | August 15, 2023 |
| 72162-2070-6 | 72162-2070 | Bryant Ranch Prepack | 60 mL in 1 BOTTLE, WITH APPLICATOR (72162-2070-6) | August 15, 2023 |
| 0713-0676-53 | 0713-0676 | Cosette Pharmaceuticals, Inc. | 1 BOTTLE in 1 CARTON (0713-0676-53) / 60 mL in 1 BOTTLE | September 13, 2016 |
| 42571-385-19 | 42571-385 | MICRO LABS LIMITED | 60 mL in 1 BOTTLE (42571-385-19) | August 16, 2021 |
| 70752-129-05 | 70752-129 | QUAGEN PHARMACEUTICALS LLC | 60 mL in 1 BOTTLE, WITH APPLICATOR (70752-129-05) | July 1, 2020 |
| 70752-130-05 | 70752-130 | QUAGEN PHARMACEUTICALS LLC | 60 mL in 1 BOTTLE, WITH APPLICATOR (70752-130-05) | July 1, 2020 |
| 71656-040-60 | 71656-040 | Saptalis Pharmaceuticals, LLC. | 60 mL in 1 BOTTLE (71656-040-60) | July 30, 2024 |
| 72162-2069 | 72162-2069 | Bryant Ranch Prepack | — | July 1, 2020 |
| 72162-2070 | 72162-2070 | Bryant Ranch Prepack | — | July 1, 2020 |
| 0713-0676 | 0713-0676 | Cosette Pharmaceuticals, Inc. | — | September 13, 2016 |
| 42571-385 | 42571-385 | MICRO LABS LIMITED | — | August 16, 2021 |
| 70752-129 | 70752-129 | QUAGEN PHARMACEUTICALS LLC | — | July 1, 2020 |
| 70752-130 | 70752-130 | QUAGEN PHARMACEUTICALS LLC | — | July 1, 2020 |
| 71656-040 | 71656-040 | Saptalis Pharmaceuticals, LLC. | — | July 30, 2024 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.